$2.4M
The seed round was co-led by Faber and Counteract to scale production of the company's BioPuff insulation.
Portfolio
5
companies
Investment by month
By category
- FinTech£108M
- AI/ML£5.5M
- MedTech£4.1M
- BioTech£1.8M
By location
- London£113M
- Galway£4.1M
- Bristol£1.8M
Portfolio companies
Abtrace
Abtrace uses machine learning and artificial intelligence to transform the detection and treatment of chronic health conditions.
LM
Luminate Medical
Luminate Medical develops portable medical devices to prevent chemotherapy induced hair loss.
P
Ponda
Ponda produces plant-based thermal insulation from wetland crops to replace down.
Updraft
Updraft provides loan refinancing solutions to help members understand their financial profiles and pay off expensive debt.
iLoF
iLoF develops an artificial intelligence powered photonics platform for personalised medicine.
Team
Sofia Santos
Partner
Sofia is a partner at Faber, having previously worked as an investment manager and venture developer at Faber Ventures. Her earlier career includes consulting roles at Jason Associates, Ray Human Capital, and SDO Consultoria.
LinkedInRecent investments
£108M
The £108m investment was led by backers including NatWest, LC Nueva, and Auluk Investments to fund product development and growth.
"We are thrilled to close this latest round of funding, where our debt and equity partners have demonstrated their belief in Updraft’s team and our mission, particularly in the current macroeconomic environment. It is a testament to what Updraft is trying to do; provide real solutions to customers to help them find their financial freedom. We have big ambitions planned for 2023, and this recent fundraiser puts us in a great position to help even more people."
£3.4M
iLoF secures 3.38m in seed funding led by Faber to accelerate personalized drug discovery platforms.
The seed round was led by Faber with participation from international venture funds to support clinical trial operations.
"For hundreds of years, treatments have been developed with the assumption they will work for everyone. However, each person is different, and for many severe diseases such as Alzheimer’s, multiple factors can contribute to the effectiveness of a treatment on a given patient."
$5.0M
The financing round was backed by investors including Elkstone Capital, SciFounders, and Faber.
"Our mission is to revolutionise the user experience of healthcare. We do that by building medical devices with a patient-first approach, and focusing on the needs that truly matter to patients. This funding round will allow us to complete first in patient clinical trials of our innovative Lily Device, and accelerate our path to market launch and patient impact in 2024"
£2.1M
The funding round was led by Faber with participation from Ganexa Capital and Innovate UK.
"As it stands, the management of long-term health conditions is an inefficient process for patients and their GP practice. It involves multiple appointments, duplication of tests, and tons of admin. It doesn’t deliver the best for patients and also wastes valuable NHS time and resources. Abtrace is working at the interface of AI and healthcare to transform this."
